ReviewPharmaceutics2025
The Convergence of Polymer Science and Predictive Modeling for Noninvasive Glucose Monitoring.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global effort to manage diabetes effectively is driving continuous innovation in glucose monitoring devices. While current systems have improved patient care, persistent challenges with sensor stability and invasiveness highlight the need for advanced, patient-friendly technologies. A particularly promising frontier is emerging from the convergence of advanced polymer science and artificial intelligence (AI), opening new pathways for noninvasive biosensing. This feature review provides a comprehensive overview of polymer-based "hardware", such as molecularly imprinted polymers (MIPs), conductive polymer hydrogels (CPHs), and functional coatings, which offer robust and biocompatible alternatives to traditional enzyme-based sensors. Concurrently, we examine (AI) "software", including machine learning and predictive modeling, which enable reliable interpretation of complex biosignals for real-time glucose monitoring. Furthermore, this review highlights critical challenges in scalability, long-term in vivo stability, regulatory approval, and clinical adoption, while discussing strategies for successful translation into pharmaceutical technology and medical devices. By mapping the current landscape and future directions, this review aims to guide research toward the next generation of intelligent, patient-centric, noninvasive glucose monitoring platforms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.